The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Angelini; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Serono; MSD
Speakers' Bureau - Bristol-Myers Squibb; EUSA Pharma; General Electric; Ipsen; MSD
Expert Testimony - EUSA Pharma; Pfizer
Travel, Accommodations, Expenses - Roche
A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).
 
Thomas Powles
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Alexandra Drakaki
Employment - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I); Dyania Health (I)
Leadership - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); ATTICA SCIENCES; Dyania Health (I); Kyn therapeutics (I); Moderna Therapeutics (I); PROTEAS BIOANALYTICS (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; DYANIA HEALTH; Exelixis; Janssen; Merck; PACT Pharma; RADMETRIX; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); BMS (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Kite/Gilead; Merck Sharp & Dohme (Inst); Seattle Genetics/Astellas (Inst)
Patents, Royalties, Other Intellectual Property - My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen
 
Jeremy Yuen-Chun Teoh
Honoraria - Ferring; Janssen
Consulting or Advisory Role - Ferring; George Clincal; Janssen
Research Funding - AstraZeneca; Bristol-Myers Squibb
 
Enrique Grande
Honoraria - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Eisai; Eusa Pharma; EUSA Pharma; Genzyme; IPSEN; Janssen-Cilag; Lexicon; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ipsen (Inst); Lexicon (Inst); Molecular Templates (Inst); Pfizer (Inst); Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Roche/Genentech
 
Mario Fontes-Sousa
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Novartis; Pfizer; Roche
 
Camillo Porta
No Relationships to Disclose
 
Esther Wu
Employment - AstraZeneca
 
Erik T. Goluboff
Employment - AstraZeneca
 
Svetlana Ho
Employment - AstraZeneca
 
Stephan Hois
Employment - AstraZeneca
 
Ashok Kumar Gupta
Employment - AstraZeneca
 
James W.F. Catto
Honoraria - Abbott Laboratories
Consulting or Advisory Role - AstraZeneca/MedImmune; Ferring; Janssen; Roche
Speakers' Bureau - ASCO; AstraZeneca/MedImmune; MSD Oncology; Nucleix; Roche
Travel, Accommodations, Expenses - European Association of Urology